Thrivent Financial for Lutherans Buys 250,833 Shares of Haemonetics Co. (NYSE:HAE)

Thrivent Financial for Lutherans boosted its position in shares of Haemonetics Co. (NYSE:HAE) by 29.5% during the third quarter, Holdings Channel.com reports. The fund owned 1,100,183 shares of the medical instruments supplier’s stock after acquiring an additional 250,833 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Haemonetics were worth $88,433,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Quarry LP purchased a new position in Haemonetics during the second quarter valued at $39,000. Covestor Ltd grew its stake in shares of Haemonetics by 184.8% in the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Haemonetics in the 2nd quarter worth about $82,000. Canada Pension Plan Investment Board bought a new position in shares of Haemonetics in the 2nd quarter valued at about $83,000. Finally, EntryPoint Capital LLC purchased a new position in Haemonetics in the first quarter worth about $86,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on HAE shares. Bank of America began coverage on Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. Citigroup decreased their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. Barrington Research restated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a report on Friday, November 8th. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. Finally, CL King started coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 target price on the stock. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Trading Down 1.7 %

NYSE HAE opened at $89.22 on Monday. The company’s 50-day simple moving average is $77.55 and its two-hundred day simple moving average is $82.62. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of 37.02, a price-to-earnings-growth ratio of 1.39 and a beta of 0.32. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $0.99 earnings per share. Equities analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.